Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
Bulletin Du Cancer|July 10, 2017
[Clinical research activity of the French cancer cooperative network: Overview and perspectives]Claire Dubois, Franck Morin, Denis Moro-Sibilot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global StudySai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, et al.
The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.
Future Oncology (London, England)|June 13, 2019
Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patientsAurélie Swalduz, Pierre-Jean Souquet, Maurice Pérol, et al.
The European Respiratory Journal|October 12, 2013
Second-line therapy in elderly patients with advanced nonsmall cell lung cancerElisabeth Quoix, Virginie Westeel, Lionel Moreau, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Lancet (London, England)|January 1, 2016
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialGérard Zalcman, Julien Mazieres, Jacques Margery, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC PatientsGiorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trialPierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancerMartin Reck, Luis Paz-Ares, Paolo Bidoli, et al.
Pageof 16